Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Rare Tumor × atezolizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 51 Carcinoma, Hepatocellular 27 Breast Neoplasms 24 Small Cell Lung Carcinoma 18 Triple Negative Breast Neoplasms 17 Lung Neoplasms 16 Urinary Bladder Neoplasms 14 Neoplasms 14 Neoplasm Metastasis 14 Melanoma 14 Carcinoma, Transitional Cell 14 Colorectal Neoplasms 13 Uterine Cervical Neoplasms 9 Head and Neck Neoplasms 7 Carcinoma, Renal Cell 7 Stomach Neoplasms 6 Recurrence 6 Prostatic Neoplasms 6 Squamous Cell Carcinoma of Head and Neck 5 Sarcoma 5 Mesothelioma, Malignant 5 Liver Neoplasms 5 Carcinoma, Squamous Cell 5 Ovarian Neoplasms 4 Carcinoma, Merkel Cell 4 Thoracic Neoplasms 3 Solid Tumors 3 Rectal Neoplasms 3 Lymphoma, Follicular 3 Lymphoma 3

Interventions

sintilimab 1 pyrotinib 1 palbociclib 1 niraparib 1 dacomitinib 1 aumolertinib 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Imatinib Mesylate 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Rare Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡